178 related articles for article (PubMed ID: 31230375)
1. Impact of induction immunosuppression on patient survival in heart transplant recipients treated with tacrolimus and mycophenolic acid in the current allocation era.
Amin AA; Araj FG; Ariyamuthu VK; Drazner MH; Ayvaci MUS; Mammen PPA; Mete M; Urey MA; Tanriover B
Clin Transplant; 2019 Aug; 33(8):e13651. PubMed ID: 31230375
[TBL] [Abstract][Full Text] [Related]
2. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
[TBL] [Abstract][Full Text] [Related]
3. Acute Rejection Rates and Graft Outcomes According to Induction Regimen among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate.
Tanriover B; Jaikaransingh V; MacConmara MP; Parekh JR; Levea SL; Ariyamuthu VK; Zhang S; Gao A; Ayvaci MUS; Sandikci B; Rajora N; Ahmed V; Lu CY; Mohan S; Vazquez MA
Clin J Am Soc Nephrol; 2016 Sep; 11(9):1650-1661. PubMed ID: 27364616
[TBL] [Abstract][Full Text] [Related]
4. Induction regimen and survival in simultaneous heart-kidney transplant recipients.
Ariyamuthu VK; Amin AA; Drazner MH; Araj F; Mammen PPA; Ayvaci M; Mete M; Ozay F; Ghanta M; Mohan S; Mohan P; Tanriover B
J Heart Lung Transplant; 2018 May; 37(5):587-595. PubMed ID: 29198930
[TBL] [Abstract][Full Text] [Related]
5. Lack of Benefit and Potential Harm of Induction Therapy in Simultaneous Liver-Kidney Transplants.
AbdulRahim N; Anderson L; Kotla S; Liu H; Ariyamuthu VK; Ghanta M; MacConmara M; Tujios SR; Mufti A; Mohan S; Marrero JA; Vagefi PA; Tanriover B
Liver Transpl; 2019 Mar; 25(3):411-424. PubMed ID: 30506870
[TBL] [Abstract][Full Text] [Related]
6. Primary pediatric live-donor-kidney transplant-recipients' outcomes by immunosuppression induction received in the United States.
Riad S; Jackson S; Chinnakotla S; Verghese P
Pediatr Transplant; 2021 Aug; 25(5):e13925. PubMed ID: 33333629
[TBL] [Abstract][Full Text] [Related]
7. Impact of induction immunosuppression on survival in heart transplant recipients: a contemporary analysis of agents.
Whitson BA; Kilic A; Lehman A; Wehr A; Hasan A; Haas G; Hayes D; Sai-Sudhakar CB; Higgins RS
Clin Transplant; 2015 Jan; 29(1):9-17. PubMed ID: 25284138
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2 receptor antagonist compared with antithymocyte globulin induction therapy in kidney transplantation from donors after cardiac death.
Peng W; Liu G; Xie W; Huang H; Wu J; Shou Z; Chen J
Int J Clin Pract Suppl; 2015 May; (183):23-8. PubMed ID: 26177071
[TBL] [Abstract][Full Text] [Related]
9. Primary pediatric deceased-donor kidney transplant recipients outcomes by immunosuppression induction received in the United States.
Riad S; Jackson S; Chinnakotla S; Verghese P
Pediatr Transplant; 2021 Aug; 25(5):e13928. PubMed ID: 33314638
[TBL] [Abstract][Full Text] [Related]
10. Incidence of cytomegalovirus in cardiac transplant recipients receiving induction immunosuppression with antithymocyte globulin.
Jewani PK; Pouch SM; Kissling KT
Clin Transplant; 2018 Nov; 32(11):e13420. PubMed ID: 30290013
[TBL] [Abstract][Full Text] [Related]
11. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
12. The impact of IL2ra induction therapy in kidney transplantation using tacrolimus- and mycophenolate-based immunosuppression.
Gralla J; Wiseman AC
Transplantation; 2010 Sep; 90(6):639-44. PubMed ID: 20595929
[TBL] [Abstract][Full Text] [Related]
13. Anti-thymocyte globulin induction with delayed introduction of tacrolimus preserves renal function in pediatric liver transplant recipients.
Rogers ME; Ambrosino T; Hatcher L; Bondoc A; Tiao G; Peters AL
Pediatr Transplant; 2023 Jun; 27(4):e14509. PubMed ID: 36919408
[TBL] [Abstract][Full Text] [Related]
14. Rabbit anti-thymocyte globulin (rATG) versus IL-2 receptor antagonist induction therapies in tacrolimus-based immunosuppression era: a meta-analysis.
Ali H; Soliman KM; Shaheen I; Kim JJ; Kossi ME; Sharma A; Pararajasingam R; Halawa A
Int Urol Nephrol; 2020 Apr; 52(4):791-802. PubMed ID: 32170593
[TBL] [Abstract][Full Text] [Related]
15. Induction Therapy With ATG Compared With Anti-IL2 Basiliximab in Low-Immunologic Risk Kidney Transplant Recipients.
Dedinská I; Graňák K; Vnučák M; Skálová P; Laca Ĺ; Krivuš J; Galajda P; Mokáň M
Transplant Proc; 2019 Dec; 51(10):3259-3264. PubMed ID: 31732198
[TBL] [Abstract][Full Text] [Related]
16. Influence of induction modality on the outcome of deceased donor kidney transplant recipients discharged on steroid-free maintenance immunosuppression.
Sureshkumar KK; Thai NL; Hussain SM; Ko TY; Marcus RJ
Transplantation; 2012 Apr; 93(8):799-805. PubMed ID: 22290269
[TBL] [Abstract][Full Text] [Related]
17. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.
Knight RJ; Graviss EA; Nguyen DT; Kuten SA; Patel SJ; Gaber L; Gaber AO
Clin Transplant; 2018 Jun; 32(6):e13265. PubMed ID: 29676018
[TBL] [Abstract][Full Text] [Related]
18. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients: three-yr results of a single-center prospective clinical trial.
Favi E; Spagnoletti G; Salerno MP; Pedroso JA; Romagnoli J; Citterio F
Clin Transplant; 2013; 27(4):E359-67. PubMed ID: 23710603
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus vs mycophenolate moftile in Tacrolimus based therapy following induction with Antithymocyte globulin promotes regulatory T cell expansion and inhibits RORγt and T-bet expression in kidney transplantation.
Jamali S; Sarafnejad A; Ahmadpoor P; Nafar M; Karimi M; Eteghadi A; Yekaninejad MS; Amirzargar AA
Hum Immunol; 2019 Sep; 80(9):739-747. PubMed ID: 30597187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
